277 related articles for article (PubMed ID: 28676069)
1. Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature.
Derrett-Smith EC; Martyanov V; Chighizola CB; Moinzadeh P; Campochiaro C; Khan K; Wood TA; Meroni PL; Abraham DJ; Ong VH; Lafyatis R; Whitfield ML; Denton CP
Arthritis Res Ther; 2017 Jul; 19(1):156. PubMed ID: 28676069
[TBL] [Abstract][Full Text] [Related]
2. Molecular subsets in the gene expression signatures of scleroderma skin.
Milano A; Pendergrass SA; Sargent JL; George LK; McCalmont TH; Connolly MK; Whitfield ML
PLoS One; 2008 Jul; 3(7):e2696. PubMed ID: 18648520
[TBL] [Abstract][Full Text] [Related]
3. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
4. Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis.
Moon SJ; Bae JM; Park KS; Tagkopoulos I; Kim KJ
Ann Rheum Dis; 2019 Jun; 78(6):817-825. PubMed ID: 30952646
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against specific extractable nuclear antigens (ENAs) as diagnostic and prognostic tools and inducers of a profibrotic phenotype in cultured human skin fibroblasts: are they functional?
Corallo C; Cheleschi S; Cutolo M; Soldano S; Fioravanti A; Volpi N; Franci D; Nuti R; Giordano N
Arthritis Res Ther; 2019 Jun; 21(1):152. PubMed ID: 31234888
[TBL] [Abstract][Full Text] [Related]
6. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis.
Bhattacharyya S; Sargent JL; Du P; Lin S; Tourtellotte WG; Takehara K; Whitfield ML; Varga J
PLoS One; 2011; 6(9):e23082. PubMed ID: 21931594
[TBL] [Abstract][Full Text] [Related]
7. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.
McCoy SS; Reed TJ; Berthier CC; Tsou PS; Liu J; Gudjonsson JE; Khanna D; Kahlenberg JM
Rheumatology (Oxford); 2017 Nov; 56(11):1970-1981. PubMed ID: 28968684
[TBL] [Abstract][Full Text] [Related]
8. Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis.
Yin H; Distler O; Shen L; Xu X; Yuan Y; Li R; Liu B; Li Q; Huang Q; Xie F; Zhang Z; Liang R; Dai X; Chen X; Li B; Yan Q; Lu L
Arthritis Rheumatol; 2024 Jan; 76(1):78-91. PubMed ID: 37488975
[TBL] [Abstract][Full Text] [Related]
9. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
[TBL] [Abstract][Full Text] [Related]
10. The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients.
Lenna S; Assassi S; Farina GA; Mantero JC; Scorza R; Lafyatis R; Farber HW; Trojanowska M
Arthritis Res Ther; 2015 Dec; 17():363. PubMed ID: 26669670
[TBL] [Abstract][Full Text] [Related]
11. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon.
Higley H; Persichitte K; Chu S; Waegell W; Vancheeswaran R; Black C
Arthritis Rheum; 1994 Feb; 37(2):278-88. PubMed ID: 7510487
[TBL] [Abstract][Full Text] [Related]
13. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
14. Identification of key genes and immune profile in limited cutaneous systemic sclerosis-associated pulmonary arterial hypertension by bioinformatics analysis.
Zhang T; Huang C; Luo H; Li J; Huang H; Liu X; Zhan S
Life Sci; 2021 Apr; 271():119151. PubMed ID: 33539912
[TBL] [Abstract][Full Text] [Related]
15. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
16. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.
Corallo C; Pinto AM; Renieri A; Cheleschi S; Fioravanti A; Cutolo M; Soldano S; Nuti R; Giordano N
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):69-75. PubMed ID: 31365333
[TBL] [Abstract][Full Text] [Related]
18. Expression of NLRP3 inflammasome, cytokines and vascular mediators in the skin of systemic sclerosis patients.
Martínez-Godínez MA; Cruz-Domínguez MP; Jara LJ; Domínguez-López A; Jarillo-Luna RA; Vera-Lastra O; Montes-Cortes DH; Campos-Rodríguez R; López-Sánchez DM; Mejía-Barradas CM; Castelán-Chávez EE; Miliar-García A
Isr Med Assoc J; 2015 Jan; 17(1):5-10. PubMed ID: 25739168
[TBL] [Abstract][Full Text] [Related]
19. Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis.
Clark KE; Lopez H; Abdi BA; Guerra SG; Shiwen X; Khan K; Etomi O; Martin GR; Abraham DJ; Denton CP; Stratton RJ
Arthritis Res Ther; 2015 Mar; 17(1):73. PubMed ID: 25885360
[TBL] [Abstract][Full Text] [Related]
20. Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.
Mathes AL; Christmann RB; Stifano G; Affandi AJ; Radstake TR; Farina GA; Padilla C; McLaughlin S; Lafyatis R
Ann Rheum Dis; 2014 Oct; 73(10):1864-72. PubMed ID: 23873879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
